hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06287697 id: LOA/RAP/2019/20 briefTitle: Energy Expenditure and Body Composition of Infants and Young Children (6-24 Months Old) in Asia overallStatus: ACTIVE_NOT_RECRUITING date: 2020-01-21 date: 2024-11-30 date: 2024-11-30 date: 2024-03-01 date: 2024-03-01 name: Mahidol University class: OTHER name: International Atomic Energy Agency name: National Institute of Nutrition, Vietnam name: Faculty of Medicine, University of Ruhuna, Sri Lanka name: Pakistan Institute of Nuclear Science and Technology (PINSTECH) name: Food and Nutrition Research Institute, Philippines name: FAO briefSummary: This project is a collaboration between International Atomic Energy Agency (IAEA), FAO Regional Office for Asia and The Pacific, and Mahidol University, Thailand to carry out the study on doubly-labeled water for assessment of total energy expenditure and body composition among infants and young children aged 6-23 months old. Thailand conducted a longitudinal study with participation from 4 other countries, namely, Pakistan, Philippines, Sri Lanka and Vietnam, in undertaking the same assessments in a cross-sectional design. conditions: Energy Expenditure conditions: Body Composition conditions: Infants and Young Children conditions: Infant and Young Child Feeding studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 391 type: ACTUAL name: No intervention measure: Total Energy Expenditure measure: Body composition measure: Weight measure: Length measure: Head circumference measure: Mid-upper arm circumference measure: Triceps skinfold thickness measure: Subscapular skinfold thickness measure: Infant and Young Child Feeding (IYCF) measure: Dietary intake sex: ALL minimumAge: 6 Months maximumAge: 24 Months stdAges: CHILD facility: Institute of Nutrition, Mahidol University city: Salaya state: Nakhon Pathom zip: 73170 country: Thailand lat: 13.802 lon: 100.32111 hasResults: False
nctId: NCT06287684 id: ESICM-22 briefTitle: Molecular Endotype-Specific Dynamics of Lung Endothelial Barrier Integrity in Sepsis acronym: MENDSEP overallStatus: RECRUITING date: 2023-09-13 date: 2025-12-30 date: 2025-12-30 date: 2024-03-01 date: 2024-03-01 name: Mater Dei Hospital, Malta class: OTHER name: European Society of Intensive Care Medicine name: University of Malta briefSummary: Sepsis is a complex syndrome that causes lethal organ dysfunction due to an abnormal host response to infection. No drug specifically targeting sepsis has been approved. The heterogeneity in sepsis pathophysiology hinders the identification of patients who would benefit, or be harmed, from specific therapeutic interventions. Recent clinical genomics studies have shown that sepsis patients can be stratified as molecular endotypes, or subclasses, with important clinical implications. Classifying sepsis patients as molecular endotypes revealed that a poor prognosis endotype was characterized by immunosuppression and septic shock. Against this backdrop, the study hypothesis is that a poor prognosis for sepsis is defined by a molecular endotype reflecting impaired innate immune and endothelial barrier integrity in the primary anatomical site of infection. conditions: Sepsis conditions: Septic Shock conditions: Pneumonia studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 132 type: ESTIMATED name: Blood transcriptomics and BAL protein profiling measure: Patient stratification as transcriptomic endotypes measure: Lung endothelial barrier integrity measure: Survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mater Dei hospital, Intensive Care Unit status: RECRUITING city: Imsida zip: MSD2080 country: Malta name: Carmel Abela role: CONTACT phone: +35625450000 email: carmel.c.abela@gov.mt lat: 35.8925 lon: 14.48278 hasResults: False
nctId: NCT06287671 id: COCO briefTitle: Colorectal Omics and ofCS Proteoglycans acronym: COCO overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2028-12 date: 2032-12 date: 2024-03-01 date: 2024-03-01 name: Claus Anders Bertelsen, PhD, MD class: OTHER name: Viborg Regional Hospital briefSummary: This observational study aims to test proteomics, metabolomics and proteoglycans as predictors of postoperative complications after colorectal surgery and as biomarkers of colorectal cancer.
Participants will undergo elective colorectal resection or stoma closure. conditions: Colorectal Cancer conditions: Diverticulitis, Colonic conditions: Inflammatory Bowel Diseases conditions: Stoma Colostomy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED name: Colorectal resection or stoma closure measure: Rate of anastomotic leakage diagnosed by CT-scan or reoperation measure: Rate of major postoperative complications measure: Short-term mortality measure: Recurrence after colorectal cancer measure: Diagnostic value of omics and other biomarkers detecting colorectal cancer measure: Correlation between biomarker in plasma and tissue sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nordsjaellands Hospital city: Hillerød zip: 3400 country: Denmark name: Nanna B Hupfeld, MD role: CONTACT phone: +4548292793 email: nanna.baekvang.hupfeld.01@regionh.dk name: Claus A Bertelsen, PhD role: CONTACT phone: +4548295972 email: claus.anders.bertelsen@regionh.dk lat: 55.92791 lon: 12.30081 facility: Regionshospitalet Viborg city: Viborg zip: 8800 country: Denmark name: Uffe S Løwe, PhD role: CONTACT lat: 56.45319 lon: 9.40201 hasResults: False
nctId: NCT06287645 id: Retinal Images Dataset briefTitle: Color Fundus Photograph With Experts Labelling overallStatus: RECRUITING date: 2022-05-12 date: 2025-12-31 date: 2026-06-30 date: 2024-03-01 date: 2024-03-07 name: Pakistan Council of Scientific and Industrial Research class: OTHER name: Al-Ibrahim Eye Hospital briefSummary: This trial aims to provide a digital retinal image dataset from Pakistan, graded by three specialists according to the severity of Diabetic Retinopathy. The dataset aims to improve research and patient care. conditions: Retinal Disease conditions: Diabetic Retinopathy studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 50000 type: ESTIMATED name: Color Fundus Photography/Non-Mydriatic Opthalmic Cameras measure: Grading Diabetic Retinopathy Severity according to International Clinical Diabetic Retinopathy Severity Scale measure: Grading Diabetic Retinopathy Severity according to Early Treatment of Diabetic Retinopathy Scale measure: Finding inter-rater agreement among the graders sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Al Ibrahim Eye Hospital status: RECRUITING city: Karachi country: Pakistan name: Ghulam Mustafa role: CONTACT email: mustafabme@gmail.com lat: 24.8608 lon: 67.0104 hasResults: False
nctId: NCT06287632 id: 2024P000451 briefTitle: CPAP in Patients With Severe Obesity After Anesthesia overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-11 date: 2026-06 date: 2024-03-01 date: 2024-03-01 name: Massachusetts General Hospital class: OTHER briefSummary: The goal of this study is to compare two continuous positive airway pressure (CPAP) settings on heart and lung function in patients with severe obesity after anesthesia. The main questions it aims to answer are:
* Intervention 2: CPAP set to home settings (if OSA is present) or between 8-10 cmH20 (if OSA is not present). conditions: Obesity, Abdominal conditions: Anesthesia Morbidity conditions: Apnea, Obstructive Sleep conditions: Atelectases, Postoperative Pulmonary conditions: Ventilator Lung studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: PREVENTION masking: NONE count: 60 type: ESTIMATED name: Recruitment/ITP-CPAP (Intervention A) name: Standard CPAP (Intervention B) name: Atmospheric Pressure measure: End expiratory lung impedance measure: Regional lung ventilation measure: Right ventricular function measure: Mean pulmonary artery pressure measure: Inspiratory effort measure: Abdominal muscle thickness measure: Respiratory rate measure: Oxygen saturation measure: Systemic blood pressure sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06287619 id: 22-5685 briefTitle: Post-operative Intravenous Iron to Treat Iron-deficiency Anemia in Patients Undergoing Cardiac Surgery acronym: POAM overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12 date: 2025-06 date: 2024-03-01 date: 2024-03-07 name: University Health Network, Toronto class: OTHER name: Queen's University name: Sunnybrook Health Sciences Centre name: Heart and Stroke Foundation of Canada briefSummary: POAM is a multicenter, randomized, controlled, internal pilot trial, using a conventional, parallel group, two-armed design at 3 cardiac surgery centres in Canada. The study is designed to assess the feasibility of a future, definitive RCT investigating whether, in patients with chronic iron-deficiency anemia undergoing cardiac surgery, IV iron therapy in the postoperative period (initiated shortly after surgery, and repeated at 42 days after surgery, if needed) improves clinical outcomes (days alive and out of hospital at 90 days after surgery; DAOH-90) relative to placebo. conditions: Chronic Iron Deficiency Anaemia conditions: Cardiac Surgery studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: POAM is a multicenter, randomized, controlled, internal pilot trial, using a conventional, parallel group, two-armed design at 3 cardiac surgery centres in Canada. primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: This is a blinded study, with patients randomized to receive ferric derisomaltose (Monoferric) or placebo. Given that the products have different physical appearances, an unblinded research pharmacist will prepare the IMP then blind the appearance of the IMP for both the intervention group and control group by covering the IV bag and tubing with opaque plastic. All other clinicians, research coordinators, outcome assessors, and patients will remain blinded by using a generic product label in the patient chart and/or the electronic product name (i.e., POAM study drug dose 1 and dose 2, rather than specifying type of product used). whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Monoferric Injectable Product name: 0.9% sodium chloride solution measure: Feasibility Outcome 1: Percentage of major protocol deviations measure: Feasibility Outcome 2: Adequate patient enrollment measure: Feasibility Outcome 3: Percentage of patients lost to follow-up at 90 days sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kingston Health Sciences Centre city: Kingston state: Ontario zip: K7L 3N6 country: Canada lat: 44.22976 lon: -76.48101 facility: Sunnybrook Health Sciences Centre city: Toronto state: Ontario zip: M4N 3M5 country: Canada lat: 43.70011 lon: -79.4163 facility: Toronto General Hospital - University Health Network city: Toronto state: Ontario zip: M5G 2C4 country: Canada lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06287606 id: CTP0302 briefTitle: A Phase 3 Clinical Trials for Bowel Preparation for Colonoscopy overallStatus: ACTIVE_NOT_RECRUITING date: 2023-08-29 date: 2024-01-17 date: 2024-05-14 date: 2024-03-01 date: 2024-03-01 name: Taejoon Pharmaceutical Co., Ltd. class: INDUSTRY briefSummary: A prospective randomized study compared to the active control. Researchers compare colon cleansing in patients undergoing colonoscopy conditions: Bowel Preparation studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 161 type: ACTUAL name: CTP0302-A name: CTP0302-B name: Conventional OST measure: Ratio of subjects With successful Bowel Cleansing measure: Each segments ratio of subject with successful Bowel Cleansing measure: Comparison of Acute gastropathy probability score sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taejoon Pharmaceutical Co., Ltd. city: Seoul country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06287593 id: NeoLiq briefTitle: The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2026-12-31 date: 2027-12-31 date: 2024-03-01 date: 2024-04-24 name: Zhejiang University class: OTHER briefSummary: This study aimed to assess the value of dynamic ctDNA monitoring in guiding the development of personalized neoadjuvant treatment strategies for EGFR-mutated NSCLC patients. conditions: EGF-R Positive Non-Small Cell Lung Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 300 type: ESTIMATED name: ctDNA monitoring measure: the rate of major pathological response (MPR) measure: the rate of pathological complete response (pCR) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06287580 id: STU-2024-0140 briefTitle: Effects of Antihypertensive Drug Treatment on Brain Blood Flow, Cognition, and Regulation of Nervous System in Older Adults With Hypertension. overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2026-01-01 date: 2027-01-01 date: 2024-03-01 date: 2024-04-24 name: University of Texas Southwestern Medical Center class: OTHER briefSummary: High blood pressure (BP) is a public health problem worldwide. Nearly three-quarters of older adults (age \~60 years) in the United States have high BP. High BP links to many health problems, like stroke. Drug treatments are typically used in clinics to reduce high BP and the risk of associated health problems. However, these drug treatments may not always benefit brain health. For example, drug treatment may reduce brain blood flow, which may reduce cognitive function in older adults with high BP. Alternatively, reduced brain blood flow may cause high BP due to increased nervous system activity (the so-called "fight or flight response"). Thus, monitoring brain blood flow may help to manage high BP during drug treatment.
Results from this study will provide novel and clinically relevant information on the impact of drug treatment for high BP on brain health. Investigators expect these results will suggest that it is crucial to measure brain blood flow, which may be a therapeutic new target for BP control and brain health. conditions: Essential Hypertension conditions: Older Adults studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: chlorthalidone 25 mg name: Placebo measure: Change in Muscle sympathetic nerve activity (MSNA) from baseline at 2 weeks post intervention measure: Change in cognitive performance from baseline at 2 weeks post intervention via Stroop Color and Word Test measure: Change in cognitive performance from baseline at 2 weeks post intervention via NIH Toolbox Cognitive Battery measure: Change in Cerebral blood flow from baseline at 2 weeks post intervention sex: ALL minimumAge: 60 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Institute for Exercise and Environmental Medicine city: Dallas state: Texas zip: 75231 country: United States name: Takuro Washio, Ph.D. role: CONTACT phone: 214-345-4852 email: TakuroWashio@texashealth.org lat: 32.78306 lon: -96.80667 hasResults: False
nctId: NCT06287567 id: IIT2023078-EC-1 briefTitle: Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP) overallStatus: NOT_YET_RECRUITING date: 2024-03-20 date: 2024-09-30 date: 2024-11-30 date: 2024-03-01 date: 2024-03-04 name: Institute of Hematology & Blood Diseases Hospital, China class: OTHER briefSummary: This exploratory study is to investigate the efficacy, safety and tolerability of Lusutrombopag in the treatment of primary immune thrombocytopenia in Chinese patients who have failed first-line therapy conditions: Idiopathic Thrombocytopenic Purpura conditions: Immune Thrombocytopenia studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 17 type: ESTIMATED name: Lusutrombopag Oral Tablet measure: Percentage of Participants with a Platelet Response after 4 Weeks (Day 29) measure: Percentage of Participants with a Platelet Response after 12 Weeks (Day 85) measure: Percentage of Participants Who at least once Achieved a Platelet Count of ≥100x10^9/L in the Core Study measure: Change in Platelet Count measure: Percentage of Participants Who at least once Achieved a Platelet Count of≥50x10^9 /L during the Treatment measure: Percentage of Participants Who at least once Achieved a Platelet Count of≥100x10^9 /L during the treatment measure: Time to first Achieve a Platelet Count of ≥ 50x10^9/L measure: Time to first Achieve a Platelet Count of ≥100x10^9 /L measure: Percentage of Participants Who at least once Achieved a Platelet Coun platelet count≥30×10^9/L, a≥2-fold increase from baseline within week 1-4 and week 5-12，respectively. measure: Durable Platelet Response (platelet count ≥50×10^9/L in ≥75% of weeks) Rate measure: Cumulated Number of Weeks of Response（≥50x10^9/L） measure: Percentage of Participants with a Reduction in the use of Concomitant ITP Medications from Baseline measure: The Incidence and Rating of Bleeding Events During the Study measure: Percentage of Participants Who Required Rescue Therapy for Bleeding During the Study measure: Number of Participants With Adverse Events (AEs) measure: Change in Health-related Quality of Life Assessed by FACIT-F Scale from Baseline to Week 16 measure: Change in Health-related Quality of Life Assessed by ITP-PAG Scale from Baseline to Week 16 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Institute of Hematology & Blood Diseases Hospital city: Tianjin state: Tianjin zip: 300020 country: China lat: 39.14222 lon: 117.17667 hasResults: False
nctId: NCT06287554 id: 404/2024 briefTitle: Effect of Early Implementation of Prone Positioning acronym: prone overallStatus: COMPLETED date: 2020-03-04 date: 2022-04-20 date: 2022-04-20 date: 2024-03-01 date: 2024-03-01 name: Zulekha Hospitals class: OTHER name: Al-Azhar University briefSummary: Background and objective: The ramifications of early lung protective measures and prone positioning on the ICU length of stay rates of participants admitted to the ICU with acute respiratory distress syndrome amid the COVID-19 pandemic constitute a pivotal examination. The study aims to identify the effect of early prone positioning on the length of stay, discharge rate, and number of tracheostomized patients in the ICU. conditions: Severe Acute Respiratory Syndrome studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: OTHER count: 70 type: ACTUAL name: PRONE POSITION measure: Number of discharged patients measure: The total length of stay measure: ICU length of stay measure: Patients who underwent tracheostomy procedures sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Al-Azhar faculty of medicine city: Cairo zip: 12546 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06287541 id: 2023-SR-486 briefTitle: The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection overallStatus: RECRUITING date: 2023-07-01 date: 2025-12-01 date: 2027-07-01 date: 2024-03-01 date: 2024-03-01 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER briefSummary: The goal of this clinical trial is to evaluate the efficacy of using a urine biomarker test to guide the decision-making process regarding the necessity of reTURBT in NMIBC patients. The main question aims to answer whether patients with negative urine biomarker tests can safely avoid reTURBT without compromising recurrence-free survival. Participants who have completed the initial TURBT and tested negative for the urine biomarker will be enrolled in the study. They will then be randomized 1:2 into two groups:Group A: Participants will not receive reTURBT and Group B: Participants will undergo reTURBT. Researchers will compare the RFS rates between Group A (no reTURBT) and Group B (reTURBT) to determine if the urine biomarker test can safely spare patients from unnecessary reTURBT. conditions: Non Muscle Invasive Bladder Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants who meet the inclusion criteria are randomized 1:2 into two parallel groups. Group A: Participants assigned to this group will not undergo reTURBT. They will receive standard follow-up care as per institutional guidelines.
Group B: Participants assigned to this group will undergo reTURBT as part of their treatment protocol. Following reTURBT, they will also receive standard follow-up care. Outcome measures of recurrence rate and RFS would be compared between the two groups to determine the effectiveness and safety of the urine genetic test-guided approach compared to standard care with reTURBT.Throughout the study period, both groups are followed up simultaneously, allowing for parallel comparisons of outcomes. primaryPurpose: TREATMENT masking: NONE count: 428 type: ESTIMATED name: Urine biomarker -Guided without reTURBT measure: 2-year RFS rate measure: RFS sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Nanjing Medical University status: RECRUITING city: Nanjing state: Jiangsu zip: 210029 country: China name: Qiang Lv, Ph.D role: CONTACT email: doctorlvqiang@sina.com lat: 32.06167 lon: 118.77778 hasResults: False